Annual General Meeting of Active Biotech AB
The Annual General Meeting of Active Biotech was held on May 19, 2021. Due to the extraordinary situation as a result of the COVID-19 pandemic, the Meeting was carried out through postal voting, without any physical attendance. The following main resolutions were passed.
In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2020, the Company’s accumulated loss shall be carried forward.
The members of the Board and the CEO were discharged from liability with respect to their management of the Company for 2020.
In accordance with the Election Committee’s proposal, the Board members Michael Shalmi, Uli Hacksell, Peter Thelin, Axel Glasmacher, Aleksandar Danilovski and Elaine Sullivan were re-elected. Michael Shalmi was re-elected as Chairman of the Board and KPMG AB was re-elected as auditor.
In accordance with the Election Committee´s proposal, the Meeting resolved that fees payable to the Board shall amount to SEK 500,000 to the Chairman of the Board and SEK 200,000 to each of the other Board members who are not employed by the Company. Furthermore, the Meeting resolved that a member of the Board who performs work for the Company outside the scope of the Board work may also receive remuneration on market terms for such work performed.
Furthermore, the Meeting resolved, in accordance with the Election Committee’s proposal, that the Election Committee shall be composed of the Chairman of the Board and one member appointed by each of the three largest shareholders of the Company based on the ownership structure at the end of September 2020.
The Meeting approved the Board’s remuneration report.
In accordance with the Board’s proposal, the Meeting finally resolved to authorize the Board to, for a period that does not extend past the date of the next Annual General Meeting, with or without pre-emptive rights for the shareholders, resolve on the issue of new shares and/or convertibles, corresponding to not more than 30 percent of the total number of shares in the Company after utilization of the authorization.
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, firstname.lastname@example.org
Hans Kolam, CFO, +46 46 19 20 44, email@example.com
This information was submitted for publication, through the agency of the contact person set out above, at 14.00 p.m. CET on May 19, 2021.
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a Phase I/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is advancing to phase II for treatment of non-infectious uveitis during second half of 2021. Please visit www.activebiotech.com for more information.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Bavarian Nordic leverer vacciner til Englands beredskab i forbindelse med nye tilfælde af abekopper11.6.2021 19:12:35 CEST | pressemeddelelse
KØBENHAVN, Danmark, 11. juni 2021 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet for nylig er blevet anmodet af de engelske sundhedsmyndigheder, Public Health England (PHE) og Medicines and Health Products Regulatory Agency (MHRA), om at levere koppevaccinen IMVANEX® til vaccination i forbindelse med nye, udefrakommende tilfælde af abekopper i mennesker i England. To relaterede tilfælde er blevet bekræftet og er blevet indlagt på et hospital i Liverpool. Den ene er sandsynligvis blevet smittet i Afrika, hvorfra familien ankom et par dage inden sygdommen brød ud, mens den anden sandsynligvis er blevet smittet af det første tilfælde efter hjemkomsten. Abekopper er en sjælden, men alvorlig sygdom, der naturligt forekommer i det centrale og det vestlige Afrika. Sygdommen er beslægtet med den menneskelige koppesygdom, om end den er mindre alvorlig med en dødelighed, der er estimeret til at være fra 1-10% af tilfældene. IMVANEX (MVA-BN) er godkendt af Europa-Kommissionen til
Bavarian Nordic Assists Public Health England in Response to New Cases of Monkeypox11.6.2021 19:12:35 CEST | Press release
COPENHAGEN, Denmark, June 11, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company was recently engaged by Public Health England (PHE) and the Medicines and Health Products Regulatory Agency (MHRA) to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox in the UK. Two related cases were confirmed and admitted to a hospital in Liverpool. One was most likely infected in Africa, where the family arrived from a few days before onset of disease, and a sibling case most likely infected on UK soil by the first case. Monkeypox is a rare, but serious disease, which is endemic in Central and West Africa. The disease is quite similar to human smallpox, although it is less severe with an estimated fatality rate of 1-10%. IMVANEX (MVA-BN) is approved by the European Commission for active immunization against smallpox but has also received approval for monkeypox by the U.S. Food and Drug Administration (FDA) and Health Canada, as the only vaccine approved for
Minister Eriksen Søreide, Deputy Minister Ryabkov, and Deputy Secretary Hicks to Keynote 2021 Carnegie International Nuclear Policy Conference11.6.2021 17:30:00 CEST | Press release
Senior officials, leaders, and experts in defense, security, and nuclear policy convene for a 3-day conference on the most-pressing challenges in nuclear arms control, nonproliferation, deterrence, and security WASHINGTON, June 11, 2021 (GLOBE NEWSWIRE) -- From June 22-24, 2021, the Carnegie Endowment for International Peace will host its biennial International Nuclear Policy Conference virtually, including keynote addresses from: Ine Eriksen Søreide, Minister of Foreign Affairs for NorwaySergey Ryabkov, Deputy Minister of Foreign Affairs of the Russian FederationKathleen Hicks, U.S. Deputy Secretary of Defense Other speakers include: Izumi Nakamitsu, UN-Secretary-General and High Representative for Disarmament Affairs; Bishop Garrison, Senior Advisor to the U.S. Secretary of Defense for Human Capital and Diversity, Equity and Inclusion; Harry Harris, former U.S. ambassador to the Republic of Korea; and Maleeha Lodhi, former UN Representative for Pakistan. The full conference agenda ca
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS11.6.2021 16:20:00 CEST | Press release
Bid procedure, 2021-06-18BondsSWEDEN I/L BOND: 3114. SE0013748258. 2030-06-01 SWEDEN I/L BOND: 3111, SE0007045745, 2032-06-01 Bid date2021-06-18Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3114: 250 mln SEK +/-150 mln SEK 3111: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)3114: 250 mln SEK per bid 3111: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-06-22Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-06-11 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK TREASURY BILLS11.6.2021 16:20:00 CEST | Press release
Bid procedure, 2021-06-16BillsSWEDISH T-BILL: SE0014808747. 2021-09-15 SWEDISH T-BILL: SE0015244405, 2021-12-15 SWEDISH T-BILL: SE0015659529, 2022-03-16 Bid date2021-06-16Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SE0014808747: 1000 mln SEK +/-500 mln SEK SE0015244405: 1000 mln SEK +/-500 mln SEK SE0015659529: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)SE0014808747: 1000 mln SEK per bid SE0015244405: 1000 mln SEK per bid SE0015659529: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2021-06-18Delivery of billsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-06-11 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between t
CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER11.6.2021 16:20:00 CEST | Press release
Bid procedure, 2021-06-16CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of 2021-12-16 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2021-06-04 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2021-06-16Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SEK 250 million issued by the s
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS11.6.2021 16:20:00 CEST | Press release
Bid procedure, 2021-06-17BondsSWEDBANK HYPOTEK AB: 192. SE0010133207. 2023-03-15 STADSHYPOTEK AB: 1588, SE0011063015, 2024-03-01 SWEDISH COVERED BOND: 151, SE0013486156, 2030-06-12 SKANDINAVISKA ENSKILDA: 581, SE0013102043, 2026-12-16 LANSFORSAKRINGAR HYPOTEK: 519, SE0012324341, 2026-09-16 DANSKE HYPOTEK AB: 2512, SE0013877214, 2025-12-17 NORDEA HYPOTEK AB: 5533, SE0010442731, 2023-09-20 Bid date2021-06-17Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)192: 800 mln SEK +/-400 mln SEK 1588: 2000 mln SEK +/-1000 mln SEK 151: 700 mln SEK +/-350 mln SEK 581: 700 mln SEK +/-350 mln SEK 519: 600 mln SEK +/-300 mln SEK 2512: 200 mln SEK +/-100 mln SEK 5533: 1000 mln SEK +/-500 mln SEK Highest permitted bid volume (corresponding nominal amount)192: 800 mln SEK per bid 1588: 2000 mln SEK per bid 151: 700 mln SEK per bid 581: 700 mln SEK per bid 519: 600 mln SEK per bid 2512: 200 mln SEK per bid 5533: 1000 mln SEK per bid Lowest permitted bid volume